GlassScriptPhysician profile
Frederick Rehm Witten
NPI 1588657654
$2,837.16
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $717 · 2021: $614 · 2022: $771 · 2023: $46.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $760.15 | 2019-2020 | |
| Medtronic, INC. | $699.58 | 2021-2022 | |
| Astellas Pharma US INC | $368.81 | 2019-2021 | |
| Urogen Pharma, INC. | $137.99 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $115.63 | 2019-2023 | Aveed, Xiaflex |
| Teleflex LLC | $94.05 | 2021 | |
| Blue Earth Diagnostics | $87.07 | 2019-2021 | |
| Janssen Biotech, INC. | $61.46 | 2019-2021 | |
| Antares Pharma, INC. | $58.47 | 2020-2022 | |
| Myovant Sciences INC. | $49.11 | 2022 | |
| Abbvie INC. | $46.47 | 2022 | |
| Procept Biorobotics Corporation | $43.79 | 2021 | |
| Clarus Therapeutics INC. | $40.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.26 | 2020-2021 | |
| Accord Healthcare, INC. | $33.21 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $19.07 | 2022 | |
| Urovant Sciences INC | $17.21 | 2022 | |
| Verity Pharmaceuticals INC. | $16.54 | 2022 | |
| Merck Sharp & Dohme LLC | $16.34 | 2020 | |
| Boston Scientific Corporation | $16.09 | 2019 | |
| Axonics, INC. | $16.07 | 2022 | |
| Eisai INC. | $16.05 | 2020 | |
| Ferring Pharmaceuticals INC. | $15.86 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.12 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.91 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $14.11 | 2019 | |
| Pfizer INC. | $14.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.79 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,770.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Witten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.